Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics #00437

Submission Number:
00437
Commenter:
Robert Riffert
Organization:
The Beaverton Pharmacy Inc
State:
Michigan
Initiative Name:
Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics
Hello, We are a neighborhood local pharmacy serving a poor, needy area and because we are a retail Pharmacy we are in the highest paying Class of Trade for Pharmaceuticals.. I am vehemently opposed to the CVS/Aetna merger because: 1. According to the SEC 40% of Express scripts profits are derived from kickbacks (Rebates), I do believe CVS rebate game is higher. 2. I do not see the consumer benefitting as most if not all the profits will be kept. 3. CVS dropped reimbursement to me beginning November 2017 to 20% below my gross cost and then had the audacity to send me 1 e-mail and 2 postal letters asking me if I had enough yet and would be willing to sell to them. How is this even legal (and if it isn't who is there to enforce this). 4. For Aetna the best example I have is when they reimbursed me $1,100 for a $700 drug charging the patient $110 (10%) copay and then taking a $400 DIR fee. Basically overcharging the patient $40 and sending them into the donut hole earlier. There will be more abuse of the system if this merger is allowed to go through because 1. Greed and 2. nobody to enforce the Waste, Fraud and Abuse PBM's foster on everybody. Thank you, Rob Riffert RPh